Foundayo Approval Intensifies Oral GLP-1 Market Competition Against Novo Nordisk
Foundayo's small-molecule design is easier to manufacture with fewer dosing restrictions than Novo Nordisk's peptide-based oral Wegovy. Analysts project Lilly's combined franchise could exceed $100 billion in peak revenue.